The trade war between the United States and China has lasted for more than one year — and a resolution is nowhere in sight.World Economyread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Investors await the Fed's latest decision on monetary policy, set to be released on Wednesday stateside. The U.S. central bank is widely expected to cut rates by 25 basis...Asia Marketsread more
TransferWise posted an annual net profit of £10.3 million on revenues of £179 million.Technologyread more
Live the high life with a night's stay at Highclere Castle, the iconic stately home made famous by Downton Abbey.Spendread more
Large banking institutions face the risk of failure if interest rates in Europe continue to stay negative, warns the global chief economist of the Economist Intelligence Unit.Banksread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
Jim Cramer has always had the goal of alerting investors when an incredible opportunity reveals itself. He knows how to spot the stocks that keep heading higher without any end in sight.
For instance, the $2.3 billion drug developer Esperion Therapeutics has been on a tear lately as investors anticipate its pill that is designed to lower levels of bad cholesterol in patients who are unable to take traditional statins.
The stock more than tripled last year, and then on Tuesday the company announced promising phase 2 data for its anti-cholesterol pill that sent it to $99 from $77.
"At that point you might have thought that the run was finished, especially since Esperion announced a 1.75 million share secondary offering on Tuesday night. But you would have been wrong," the "Mad Money" host said.
The secondary deal offered $100 per share, and considering that it closed at $110 on Thursday investors could have made a killing already.
Could this stock head even higher in 2015? To find out, Cramer spoke with Esperion CEO Tim Mayleben.
"I don't know the explanation for the stock activity for sure, but we are very excited about the drug that we are developing. It's got a particularly unsexy name…but we think it's one of the most attractive drugs in development," Mayleben said.
In recent studies, the new drug was able to lower LDL cholesterol by itself and also in combination with the traditional treatment of statins.
"That's vitally important for patients who are taking a medicine like this or could take a medicine like this for the rest of their lives," the CEO added.
Read more from Mad Money with Jim Cramer
Cramer Remix: Oil news you've waited on
Starbucks CEO speaks out on race
Cramer: $$ rolling into this sector—thanks to Fed
Mayleben explained that while Regeneron, Sanofi and Amgen all have cholesterol therapies up for approval with the FDA this year, what separates Esperion from the pack is that this is a once-a-day pill that does not require injection.
"We hold the radical belief that patients will prefer an oral once-daily pill, rather than have to self-inject or go to their doctor for an injection," he said.